Etiology of mitral regurgitation setting the course in long-term survival after successful Transcatheter Edge-to-Edge Repair

Felix Ausbüttel (Marburg)1, S. Barth (Bad Neustadt a. d. Saale)2, G. Chatzis (Marburg)1, K. Sassani (Marburg)3, H. Schütt (Marburg)1, D. Fischer (Rheine)4, J. Müller (Bad Neustadt a. d. Saale)2, D. Divchev (Marburg)1, B. Schieffer (Marburg)3, U. Lüsebrink (Marburg)1, C. Wächter (Marburg)1

1Universitätsklinikum Giessen und Marburg GmbH Klinik für Innere Medizin - Schwerpunkt Kardiologie Marburg, Deutschland; 2RHÖN-KLINIKUM AG Campus Bad Neustadt Klinik für Kardiologie I - Interventionelle Kardiologie und kardiale Bildgebung Bad Neustadt a. d. Saale, Deutschland; 3Universitätsklinikum Giessen und Marburg GmbH Klinik für Kardiologie, Angiologie und internistische Intensivmedizin Marburg, Deutschland; 4Klinikum Rheine Medizinische Klinik II - Kardiologie Rheine, Deutschland

 

Background: Transcatheter Edge-to-Edge Repair (TEER) is an established therapy for patients with symptomatic high-grade mitral regurgitation (MR) and has been validated for the treatment of both functional and degenerative MR. However, there are relevant differences in clinical characteristics between the two etiologies and date on their impact on long-term survival are scarce. Therefore, we aimed to investigate the influence of MR etiology on survival after TEER.

Methods: In this multicenter cohort study, 725 patients from four German heart centers were investigated between 2011-2022. Patients were stratified according to MR etiology. Degenerative MR was present in the case of any structural alteration of the valvular apparatus. Functional MR was further divided into ventricular functional (v-FMR) and atrial functional MR (a-FMR). The former existed in the case of impaired LV function and/or LV dilatation, the latter was present in the case of LA dilatation with preserved LV function and structure. Survival time analysis was performed by using the Kaplan-Meier method.

Results: The majority of 59.6% of patients (432/725) had functional MR, which were further separated into v-FMR in 50.6% (367/725) and a-FMR in 9% (65/725) of patients. Patients with v-FMR were significantly younger, were more frequently male and had a significantly higher prevalence of CAD. Corresponding to the definition of FMR subtypes, lower LV function with higher numbers of implanted devices was seen among patients with v-FMR, as presented in Table 1. Patients with v-FMR had the poorest long-term survival while those between patients having a-FMR and degenerative MR did not differ significantly, as illustrated in Figure 1 and Table 2.

Conclusion
: Our data from a “real-world” collective emphasize that patients with v-FMR exhibit important differences in comorbidities and long-term survival compared to the further MR etiologies.


Table 1: Clinical data of patients undergoing TEER with concomitant degenerative-, atrial-functional and ventricular-functional mitral regurgitation

Variable

Overall

(n=725)

DMR

(n=293)

v-FMR

(n=367)

a-FMR

(n=65)

p-value

Age (years)

78 ± 8

80 ± 7

77 ± 8

81 ± 7

<0.0001

Male sex

63.3% (459)

59.4% (174)

69.2% (254)

48.4% (31)

0.001

euroSCORE (%)*

16% (21)

13.8% (17.5)

20.1% (25)

7.9% (10)

<0.0001

CAD

62.6% (454)

56% (164)

68.4% (251)

60.9% (39)

0.004

Pre-existing ICD

23.2% (168)

14.3% (42)

34.1% (125)

1.6% (1)

<0.0001

Pre-existing CRT

14.8% (107)

10.6% (31)

20.2% (74)

3.1% (2)

<0.0001

GFR (mL/Min)

50 ± 26

52 ± 30

47 ± 21

55 ± 24

0.1

NT-proBNP (ng/L)*

2788 (5234)

2467 (4786)

3493 (6068)

1434 (2150)

<0.0001

LVEF (%)

41 ± 15

46 ± 14

34 ± 12

59 ± 4

<0.0001


*Median + IQR

Table 2: Independent predictors of mortality in multivariable Cox regression analysis

Variable

Hazard Ratio

95%-CI

p-value

TR grade III

1.8

1.3-2.3

<0.001

NYHA class IV

1.5

1.2-2.0

0.003

Male sex

1.5

1.2-2.0

0.002

COPD

1.5

1.2-2.0

0.002

GFR <30mL/min

1.3

1.1-1.9

0.01

v-FMR

1.4

1.1-1.8

0.007

 

Diese Seite teilen